Sold as Picato. Every FDA application for this active ingredient: 1 branded and 3 generic.
As of Nov 16, 2026, FDA lists 4 applications for Ingenol Mebutate (sold as Picato), first approved Jan 23, 2012, with 1 new use approved and 0 published complete response letters.
| Jan 23, 2012 | PicatoNDA 202833 · New molecular entity | Leo Labs | 10 | Discontinued |
| Jan 7, 2019 | Ingenol MebutateANDA 209018 | Padagis Israel | 3 | Discontinued |
| Jan 9, 2019 | Ingenol MebutateANDA 209019 | Padagis Israel | 3 | Discontinued |
| — | Ingenol MebutateANDA 209086 | Actavis Labs | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA